News
DHR
219.98
+0.10%
0.23
Assessing Danaher (DHR) Valuation After Earnings Beat And Optimistic Analyst Sentiment
Simply Wall St · 8h ago
Do Wall Street Analysts Like Danaher Stock?
Barchart · 23h ago
Peering Into Danaher Corp's Recent Short Interest
Benzinga · 1d ago
Weekly Report: what happened at DHR last week (0202-0206)?
Weekly Report · 2d ago
Do Danaher’s Bioprocessing Gains and Buybacks Reveal a Sharper Strategic Focus for DHR?
Simply Wall St · 5d ago
Noteworthy ETF Outflows: IYH, GILD, PFE, DHR
NASDAQ · 5d ago
Is Danaher (DHR) Fairly Priced After Recent Share Price Weakness?
Simply Wall St · 6d ago
Danaher: The Worst Should Be Over, But Valuation Is Still Tight (Rating Downgrade)
Seeking Alpha · 02/04 09:17
The Top 5 Analyst Questions From Danaher’s Q4 Earnings Call
Barchart · 02/04 02:16
Assessing Danaher (DHR) Valuation After 2025 Sales Growth But Weaker Earnings
Simply Wall St · 02/03 06:21
Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers
Benzinga · 02/02 15:28
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Danaher (DHR) and BridgeBio Pharma (BBIO)
TipRanks · 02/02 13:50
Weekly Report: what happened at DHR last week (0126-0130)?
Weekly Report · 02/02 09:55
Danaher Automata Deal Highlights Automation Push And Mixed Share Performance
Simply Wall St · 01/30 22:36
Danaher Stock Plunge Does Not Represent A Good Entry Point
Seeking Alpha · 01/30 16:35
Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)
TipRanks · 01/30 16:10
Private Markets: Nvidia, Microsoft consider new investment in OpenAI
TipRanks · 01/30 15:51
Analysts’ Top Healthcare Picks: Danaher (DHR), Edwards Lifesciences (EW)
TipRanks · 01/30 13:31
Danaher Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Benzinga · 01/29 22:00
Danaher Is Maintained at Overweight by JP Morgan
Dow Jones · 01/29 21:28
More
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.